PFIZER INC: $769M Department of Health and Human Services Contract Vehicle
Summary
Pfizer Inc ($PFE) has been awarded a $769M contract from the CDC for the Vaccines for Children program. This represents about 1.29% of Pfizer's annual revenue and reinforces its position in the pediatric vaccine market. The contract is supported by legislative efforts like HR10857 to advance clinical development of novel treatments.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Pfizer secures $769M in VFC contract, adding ~1.3% to annual revenue.
- 2.The contract aligns with legislative push for healthcare innovation (HR10857).
- 3.Investors should watch for sustained government demand for vaccines and potential supply chain benefits for component suppliers.
Market Implications
This contract reinforces Pfizer's dominance in the vaccine market. While the immediate revenue impact is modest relative to Pfizer's size, it signals continued government spending on public health. Investors can view this as a predictable cash flow component. The broader legislative environment, including HR10857, supports further innovation in vaccine development, potentially benefiting Pfizer's pipeline. Supply chain partners like Thermo Fisher ($TMO) may also see indirect benefits from increased vaccine production demand.
Full Analysis
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc a $769M indefinite delivery/indefinite quantity contract for the Vaccines for Children (VFC) program, covering the period from April 2026 to March 2027. This program provides recommended vaccines to eligible children at no cost, and Pfizer is a key supplier of pediatric vaccines, including Prevnar 13 and others.
For Pfizer, this contract adds $769M in guaranteed revenue, which is approximately 1.29% of its FY2025 revenue of $59.6B. While not transformative, it provides a stable, predictable cash flow from a long-standing government partnership. Pfizer's vaccines segment has been a significant revenue driver, and this contract reinforces its leadership in pediatric immunization.
The contract aligns with legislative momentum in healthcare innovation. HR10857, which amends the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance next-generation clinical development of novel treatments and cures, directly supports the type of vaccine research and development that underpins programs like VFC. This bill signals continued government investment in vaccine technology and public health infrastructure.
Downstream, suppliers of vaccine components, adjuvants, and logistics services may benefit. Companies like Thermo Fisher Scientific ($TMO) and Merck KGaA (private) could see increased demand for raw materials and manufacturing support. However, the primary beneficiary is Pfizer as the prime contractor.
Historically, VFC contracts have been renewed regularly, providing multi-year revenue streams for vaccine manufacturers. This award continues that pattern, and investors can expect similar renewals in the future as the program remains a cornerstone of U.S. public health policy.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct contract award from CDC for Vaccines for Children program.
Who must act
Centers for Disease Control and Prevention (CDC) awarding to Pfizer Inc.
What happens
$769M added to Pfizer's revenue, representing approximately 1.29% of its FY2025 revenue of $59.6B.
Stock impact
This contract supports Pfizer's pediatric vaccine portfolio, which is a key part of its broader vaccines business. While $769M is meaningful, it is not transformative for a company of Pfizer's size. It provides stable, recurring revenue from a long-standing government program.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
PFIZER INC: $661M Department of Health and Human Services Contract Vehicle
HELP Copays Act
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
Biosimilars Access and Affordability Act
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
A bill to provide for digital communication of prescribing information for drugs (including biological products), and for other purposes.
Expedited Access to Biosimilars Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Contract Details
Recipient
PFIZER INC
Award Amount
$768,946,719
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Disease Control and Prevention
Contract Type
INDEFINITE DELIVERY / INDEFINITE QUANTITY
Related Bills
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →